Archive for the ‘Diabetes’ Category

The CDA’s 2003 CPGs recommend use of acetyl- salicylic acid (unless contraindicated) for all patients with evidence of cardiovascular disease, as well as those with atherosclerotic risk factors. Some consider people with diabetes to have the same high risk of myocardial infarction as people without diabetes who have had a previous myocardial infarction.23,24 This study […]

At least 63% of the patients in this study had initial monitoring parameters measured; however, achieve­ment of follow-up monitoring was much lower. The hemoglobin AK target was achieved for 93% of the patients, but less than 45% of patients achieved other laboratory targets. Less than 60% of eligible patients received recommended medications. Much controversy surrounds […]

Of the 349 patients with type 2 diabetes who first visited the Diabetes Education Centre in 2004, 167 (48%) met the inclusion criteria. The other patients were excluded because they did not meet age criteria (140 [40%]), they did not attend a formal Session 1 class (40 [11%]), or they died (causes of death unknown) […]

This quality assessment was performed at the Diabetes Education Centre of Lions Gate Hospital. The study was approved by the University of British Columbia Clinical Research Ethics Board.

INTRODUCTION Diabetes mellitus affects over 2 million Canadians. Type 2 diabetes accounts for 90% of these cases, and its incidence is increasing dramatically. Complica­tions include cardiovascular disease, stroke, hyperten­sion, dyslipidemia, nephropathy, neuropathy, and retinopathy. Diabetes and its complications cost the Canadian health care system an estimated $13.2 billion every year.

Pfizer Diabetes

18, May 2010

Occasionally, in this space, we review matters of concern to consumers and clinicians regarding clinical care. Recently, I commented on 1 on 1 health™, the consumer Web portal for GlaxoSmithKline (P&T February 2004). In this issue of P&T, I would like to add some context for another important Web portal for consumers and physicians, namely. […]

HDL also seems to be more quickly hydrolyzed in patients with insulin resistance, leading to lower HDL levels. Statins can reduce LDL levels by 18% to 55% and triglycerides by 7% to 30%; they can also increase HDL levels by 5% to 15%.